B2M and melanoma: A new mutation in MAP2K2 gene was reported, which most likely conferred resistance to dabrafenib and trametinib treatment and anti-PD1 therapies (nivolumab plus pembrolizumab), whereas a frameshift mutation in B2M was the strongest candidate alteration for progression on checkpoint inhibitor therapy in melanoma (Richmond et al., 2019).